Plain-English translation of NCT07496229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new combination treatment using GW5282 and golidocitinib for people with T-cell lymphoma, a rare type of cancer that affects immune cells. The trial has two main phases: first, doctors will find the safest and most effective dose of this medication combination, and then they'll compare it head-to-head with a standard chemotherapy treatment to see if the new approach works better.
T-cell lymphoma is difficult to treat, and current standard chemotherapy doesn't work well enough for many patients. This trial exists to see whether this new treatment combination might offer a better option with improved results.
You likely qualify if…
You likely don't qualify if…
The trial has two parts. In Part A, you'll receive increasing doses of the medication combination to find the safest level. In Part B, you'll be randomly assigned to either receive the new medication combination or the standard chemotherapy treatment, and doctors will monitor how well it works and any side effects. You'll need to visit the clinic regularly for blood tests, scans, and check-ups, and treatment will continue for several months while doctors assess how you're responding.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China